Cargando…
Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprot...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642347/ https://www.ncbi.nlm.nih.gov/pubmed/26561427 http://dx.doi.org/10.1038/srep16510 |
_version_ | 1782400348047015936 |
---|---|
author | Mizuno, Manami Miyazawa, Ken Tabuchi, Masako Tanaka, Miyuki Yoshizako, Mamoru Minamoto, Chisato Torii, Yasuyoshi Tamaoka, Yusuke Kawatani, Makoto Osada, Hiroyuki Maeda, Hatsuhiko Goto, Shigemi |
author_facet | Mizuno, Manami Miyazawa, Ken Tabuchi, Masako Tanaka, Miyuki Yoshizako, Mamoru Minamoto, Chisato Torii, Yasuyoshi Tamaoka, Yusuke Kawatani, Makoto Osada, Hiroyuki Maeda, Hatsuhiko Goto, Shigemi |
author_sort | Mizuno, Manami |
collection | PubMed |
description | Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprotegerin (OPG)-knockout mice, specifically, whether it could control osteoclasts and reduce inflammation in periodontal tissue. We examined wild-type (WT) and OPG knockout mice (OPG KO) ligated with wire around contact points on the left first and second molars. RMA was administered twice a day to half of the mice. Using micro-computed tomography, we measured the volume of alveolar bone loss between the first and second molars, and also performed histological analysis. The OPG KO RMA+ group had significantly decreased osteoclast counts, alveolar bone loss, attachment loss, and inflammatory cytokine expression 8 weeks after ligation. Thus, RMA may reduce alveolar bone loss and inflamed periodontal tissues in patients with periodontitis. |
format | Online Article Text |
id | pubmed-4642347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46423472015-11-20 Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease Mizuno, Manami Miyazawa, Ken Tabuchi, Masako Tanaka, Miyuki Yoshizako, Mamoru Minamoto, Chisato Torii, Yasuyoshi Tamaoka, Yusuke Kawatani, Makoto Osada, Hiroyuki Maeda, Hatsuhiko Goto, Shigemi Sci Rep Article Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprotegerin (OPG)-knockout mice, specifically, whether it could control osteoclasts and reduce inflammation in periodontal tissue. We examined wild-type (WT) and OPG knockout mice (OPG KO) ligated with wire around contact points on the left first and second molars. RMA was administered twice a day to half of the mice. Using micro-computed tomography, we measured the volume of alveolar bone loss between the first and second molars, and also performed histological analysis. The OPG KO RMA+ group had significantly decreased osteoclast counts, alveolar bone loss, attachment loss, and inflammatory cytokine expression 8 weeks after ligation. Thus, RMA may reduce alveolar bone loss and inflamed periodontal tissues in patients with periodontitis. Nature Publishing Group 2015-11-12 /pmc/articles/PMC4642347/ /pubmed/26561427 http://dx.doi.org/10.1038/srep16510 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Mizuno, Manami Miyazawa, Ken Tabuchi, Masako Tanaka, Miyuki Yoshizako, Mamoru Minamoto, Chisato Torii, Yasuyoshi Tamaoka, Yusuke Kawatani, Makoto Osada, Hiroyuki Maeda, Hatsuhiko Goto, Shigemi Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
title | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
title_full | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
title_fullStr | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
title_full_unstemmed | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
title_short | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
title_sort | reveromycin a administration prevents alveolar bone loss in osteoprotegerin knockout mice with periodontal disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642347/ https://www.ncbi.nlm.nih.gov/pubmed/26561427 http://dx.doi.org/10.1038/srep16510 |
work_keys_str_mv | AT mizunomanami reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT miyazawaken reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT tabuchimasako reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT tanakamiyuki reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT yoshizakomamoru reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT minamotochisato reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT toriiyasuyoshi reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT tamaokayusuke reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT kawatanimakoto reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT osadahiroyuki reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT maedahatsuhiko reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease AT gotoshigemi reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease |